Acorda, AstraZeneca Tell Justices To Skip ANDA Venue Case
Acorda and AstraZeneca urged the U.S. Supreme Court not to hear an appeal by Mylan challenging the Federal Circuit's rule that generic-drug makers can face patent suits anywhere they may one...To view the full article, register now.
Already a subscriber? Click here to view full article